Carbohydrate oxidation disorders of skeletal muscle

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 5, Issue 6, 2002, Pages 611-617

  Vorgerd, Matthias ^a,c   Zange, Jochen ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b GERMAN AEROSPACE CENTER DLR   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

31P magnetic resonance spectroscopy; Genetics; Muscle glycogenosis; Therapy

Indexed keywords

ALPHA GLUCOSIDASE; BRANCHED CHAIN AMINO ACID; CREATINE; ISOLEUCINE; LEUCINE; PYRIDOXINE; RECOMBINANT ENZYME; VALINE; PHOSPHORUS;

CARBOHYDRATE METABOLISM; CLINICAL TRIAL; DIET SUPPLEMENTATION; ENZYME REPLACEMENT; GENE THERAPY; GENOTYPE PHENOTYPE CORRELATION; GLYCOGEN STORAGE DISEASE; GLYCOGEN STORAGE DISEASE TYPE 13; GLYCOGEN STORAGE DISEASE TYPE 2; GLYCOGEN STORAGE DISEASE TYPE 5; GLYCOGEN SYNTHESIS; HUMAN; MUSCLE CONTRACTURE; MUSCLE WEAKNESS; MYALGIA; MYOGLOBINURIA; MYOPATHY; NONHUMAN; OXIDATION; PATHOPHYSIOLOGY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; REVIEW; ANIMAL; DISEASE MODEL; ENZYMOLOGY; GENETICS; GENOTYPE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION REDUCTION REACTION; PATHOLOGY; PHENOTYPE; SKELETAL MUSCLE;

ANIMALS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENOTYPE; GLYCOGEN STORAGE DISEASE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MUSCLE, SKELETAL; OXIDATION-REDUCTION; PHENOTYPE; PHOSPHORUS ISOTOPES;

EID: 1842441116     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200211000-00003     Document Type: Review

References (42)

1. DiMauro S, Lamperti C. Muscle glycogenoses. Muscle Nerve 2001; 24:984-999. An excellent review on muscle glycogenosis with a focus on clinical pathophysiologic and molecular genetic findings.
2. Tsujino S, Nonaka I, DiMauro S. Glycogen storage myopathies. Neurol Clin 2000; 18:125-150.
3. Kreuder J, Borkhardt A, Repp R, et al. Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med 1996; 334:1100-1104.
4. Comi GP, Fortunato F, Lucchiari S, et al. Beta-enolase deficiency, a new metabolic myopathy of distal glycolysis. Ann Neurol 2001; 50:202-207. This is the first description of β-enolase deficiency, the newest identified glycolytic defect causing exercise intolerance.
5. DiMauro S, Andreu AL, Bruno C, et al. Myophosphorylase deficiency (glycogenosis type V: McArdle disease). Curr Mol Med 2002; 2:189-196. A comprehensive review on McArdle disease, the most common carbohydrate oxidative disorder causing exercise intolerance.
6. Hirschhorn R, Reuser AJJ. Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency. In: Beadet AL, Valle D, Sly WS, editors: the metabolic and molecular bases of inherited disease, 8th ed. New York McGraw-Hill; 2001. pp. 3389-3420. An excellent review on Pompe disease is presented.
7. Livingstone C, Chinnery PF, Turnbull DM. The ischaemic lactate-ammonia test. Ann Clin Biochem 2001; 38:304-310.
8. Hogrel JY, Laforet P, Ben Yaou R, et al. A non-ischemic forearm exercise test for the screening of patients with exercise intolerance. Neurology 2001; 56:1733-1738. This paper describes a non-ischaemic exercise test to screen patients with a suspected metabolic myopathy. This method overcomes the major drawbacks of the historically ischaemic forearm test.
9. Lindner A, Reichert N, Eichhorn M, et al. Acute compartment syndrome after forearm ischemic work test in a patient with McArdle's disease. Neurology 2001; 56:1779-1780.
10. Hadjigeorgiou GM, Papadimitriou A, Musumeci O, et al. A new stop codon mutation (Y52X) in the myophosphorylase gene in a Greek patient with McArdle's disease. J Neurol Sci 2002; 194:83-86.
11. Martin MA, Rubio JC, Buchbinder J, et al. Molecular heterogeneity of myophosphorylase deficiency (McArdle's disease): a genotype-phenotype correlation study. Ann Neurol 2001; 50:574-581.
12. Deschauer M, Opalka JR, Lindner A, et al. A novel nonsense mutation (R269X) in the myophosphorylase gene in a patient with McArdle disease. Mol Genet Metab 2001; 74:489-491.
13. Fernandez-Hojas R, Huie ML, Navarro C, et al. Identification of six novel mutations in the acid alpha-glucosidase gene in three Spanish patients with infantile onset glycogen storage disease type II (Pompe disease). Neuromusc Disord 2002; 12:159-166.
14. Hesselink RP, Gorselink M, Schaart G, et al. Impaired performance of skeletal muscle in α-glucosidase knockout mice. Muscle Nerve 2002; 25:873-883. This is a detailed study on the pathophysiological mechanism in α-glucosidase knockout mice. Large clusters of non-contractile material present in the cytoplasm hampered muscle contractile function, whereas the measured energy status was not changed.
15. 31P MRS data are used in model equations describing metabolic fluxes and their control in working healthy muscle.
16. Kemp GJ. Studying metabolic regulation in human muscle. Biochem Soc Trans 2000; 28:100-103.
17. Jeneson JA, Westerhoff HV, Kushmerick MJ. A metabolic control analysis of kinetic controls in ATP free energy metabolism in contracting skeletal muscle. Am J Physiol 2000; 279:C813-C832.
18. Vicini P, Kushmerick MJ. Cellular energetics analysis by a mathematical model of energy balance: estimation of parameters in human skeletal muscle. Am J Physiol 2000; 279:C213-C224.
19. 31P MRS data in model-based equations.
20. 31P MRS data in model-based equations.
21. Argov Z, Arnold DL. MR spectroscopy and imaging in metabolic myopathies. Neurol Clin 2000; 18:35-52.
22. Argov Z, Löfberg M, Arnold DL. Insights into muscle diseases gained by phosphorus magnetic resonance spectroscopy. Muscle Nerve 2000; 23:1316-1334.
23. Duboc D, Jehenson P, Tran Dinh S, et al. Phosphorus NMR spectroscopy study of muscle enzyme deficiencies involving glycogenolysis and glycolysis. Neurology 1987; 37:663-671.
24. 31P magnetic resonance spectroscopy. Neuromusc Disord 1998; 8:480-488.
25. Van den Hout JM, Reuser AJ, de Klerk JB, et al. Enzyme therapy for Pompe disease with recombinant human alpha-giucosidase from rabbit milk. J Inherit Metab Dis 2001; 24:266-274. This open study provides promising results of recombinant enzyme replacement in four patients with infantile Pompe disease. This well-documented study should stimulate pharmaceutical clinical research.
26. Ding EY, Hodges BL, Hu H, et al. Long-term efficacy after (E1-, polymerase) adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice. Hum Genet Ther 2001; 12:955-965. This paper demonstrates that a single intravenous injection of an adenovirus-based vector encoding α-glucosidase into α-glucosidase knockout mice can allow for persistence of the vector and long-term detection of glucosidase in muscle.
27. Raben N, Lu N, Nagaraju K, et al. Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy. Hum Mol Genet 2001; 10:2039-2047. Using α-glucosidase knockout mice, this study demonstrates that cultured liver cells could potentially provide a source of the recombinant protein, and that the skeletal and cardiac muscle pathology improved if the treatment was begun early.
28. Lin CY, Ho CH, Hsieh YH, et al. Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency. Gene Ther 2002; 9:554-563. In this study of α-glucosidase-deficient Japanese quails as an animal model, transduced skeletal muscle transiently expressed α-glucosidase and histologically improved.
29. Martin-Touaux E, Puech JP, Chateau D, et al. Muscle as a putative producer of acid alpha-glucosldase for glycogenosis type II gene therapy. Hum Mol Genet 2002; 11:1637-1645. This study shows that in transduced skeletal muscle of an α-glucosidase knockout mouse a strong expression of α-glucosidase in the injected muscle, secretion into plasma, and uptake by peripheral skeletal and cardiac muscle were detected. Skeletal muscle can be considered as a secretory organ for gene therapy in GSD II.
30. Argov Z, Bank WJ, Maris J, et al. Muscle energy metabolism in McArdle's syndrome by in vivo phosphorus magnetic resonance spectroscopy. Neurology 1987; 37:1720-1724.
31. Braakhekke JP, de Bruin MI, Stegeman DF, et al. The second wind phenomenon in McArdle's disease. Brain 1986; 109:1087-1101.
32. Dorin RI, Field JC, Boyle PJ, et al. Insulin resistance limits glucose utilization and exercise tolerance in myophosphorylase deficiency and NIDDM. J Appl Physiol 1996; 81:1273-1278.
33. Nielsen JN, Vissing J, Wojtaszewski JF, et al. Decreased insulin action in skeletal muscle from patients with McArdle's disease. Am J Physiol Endocrinol Metab 2002; 282:E1267-E1275.
34. Steele IC, Patterson VH, Nicholis DP. A double blind, placebo controlled, crossover trial of D-ribose in McArdle's disease. J Neurol Sci 1996; 136:174-177.
35. Wagner DR, Zollner N. McArdle's disease: successful symptomatic therapy by high dose oral administration of ribose. Klin Wochenschr 1991; 69:92.
36. Mineo I, Kono N, Yamada Y, et al. Glucose infusion abolishes the excessive ATP degradation in working muscles of a patient with McArdle's disease. Muscle Nerve 1990; 13:618-620.
37. MacLean D, Vissing J, Vissing SF, et al. Oral branched-chain amino acids do not improve exercise capacity in McArdle disease. Neurology 1998; 51:1456-1459.
38. Phoenix J, Hopkins P, Bartram C, et al. Effect of vitamin B6 supplementation in McArdle's disease: a strategic case study. Neuromusc Disord 1998; 8:210-212.
39. Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 2001; 49:561-574. An excellent summary on the various functions of creatine in the energy metabolism of muscle and nerve. The potential of creatine supplemention in neurological disorders is underlined by findings from recent studies.
40. Tarnopolsky MA, Parshad A, Walzel B, et al. Creatine transporter and mitochondrial creatine kinase protein content in myopathies. Muscle Nerve 2001; 24:682-688.
41. Vorgerd M, Zange J, Kley R, et al. Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study. Arch Neurol 2002; 59:97-101.
42. Vorgerd M, Grehl T, Jager M, et al. Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial. Arch Neurol 2000; 57:956-963.